Julie A. Krueger

1.6k total citations
31 papers, 906 citations indexed

About

Julie A. Krueger is a scholar working on Molecular Biology, Organic Chemistry and Hematology. According to data from OpenAlex, Julie A. Krueger has authored 31 papers receiving a total of 906 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 13 papers in Organic Chemistry and 11 papers in Hematology. Recurrent topics in Julie A. Krueger's work include Chemical Synthesis and Analysis (10 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Chemical synthesis and pharmacological studies (6 papers). Julie A. Krueger is often cited by papers focused on Chemical Synthesis and Analysis (10 papers), Blood Coagulation and Thrombosis Mechanisms (10 papers) and Chemical synthesis and pharmacological studies (6 papers). Julie A. Krueger collaborates with scholars based in United States, Germany and Canada. Julie A. Krueger's co-authors include Stephen J. Gardell, Mark J. Evans, Shuguang Wang, Sidney D. Lewis, Bobby J. Lucas, Helen B. Hartman, Chris Petucci, Joseph P. Vacca, Youwei Yan and Adel M. Naylor-Olsen and has published in prestigious journals such as Journal of Biological Chemistry, Blood and Biochemistry.

In The Last Decade

Julie A. Krueger

30 papers receiving 856 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Julie A. Krueger United States	18	394	237	198	140	123	31	906
Daniel R. McMasters United States	22	562 1.4×	373 1.6×	152 0.8×	62 0.4×	98 0.8×	40	1.2k
Ana Negri Spain	18	649 1.6×	146 0.6×	119 0.6×	130 0.9×	49 0.4×	31	1.1k
Michèle Masquelier Sweden	17	427 1.1×	103 0.4×	218 1.1×	88 0.6×	161 1.3×	34	962
Philip D. Edwards United States	24	712 1.8×	504 2.1×	221 1.1×	67 0.5×	144 1.2×	32	1.6k
Richard M. Keenan United States	23	576 1.5×	394 1.7×	175 0.9×	167 1.2×	66 0.5×	39	1.4k
Christine Luong United States	16	549 1.4×	387 1.6×	262 1.3×	182 1.3×	35 0.3×	19	1.5k
Vanessa Desplat France	20	323 0.8×	683 2.9×	103 0.5×	152 1.1×	40 0.3×	52	1.2k
Richard Sedrani Switzerland	16	783 2.0×	343 1.4×	237 1.2×	27 0.2×	301 2.4×	23	1.6k
Wendell Wierenga United States	20	519 1.3×	487 2.1×	98 0.5×	82 0.6×	87 0.7×	53	1.1k
Angela Smallwood United States	19	533 1.4×	378 1.6×	252 1.3×	308 2.2×	51 0.4×	26	1.4k

Countries citing papers authored by Julie A. Krueger

Since Specialization

Citations

This map shows the geographic impact of Julie A. Krueger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Julie A. Krueger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Julie A. Krueger more than expected).

Fields of papers citing papers by Julie A. Krueger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Julie A. Krueger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Julie A. Krueger. The network helps show where Julie A. Krueger may publish in the future.

Co-authorship network of co-authors of Julie A. Krueger

This figure shows the co-authorship network connecting the top 25 collaborators of Julie A. Krueger. A scholar is included among the top collaborators of Julie A. Krueger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Julie A. Krueger. Julie A. Krueger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Degenhardt, Yan, Jun Guan, Peter T. Morley, et al.. (2022). Abstract 6268: Discovery and characterization of the CD96 antibody GSK6097608, a high-affinity, antagonistic anti-CD96 antibody for cancer immunotherapy. Cancer Research. 82(12_Supplement). 6268–6268. 1 indexed citations

Parrish, Cynthia A., et al.. (2019). Mechanistic MALDI-TOF Cell-Based Assay for the Discovery of Potent and Specific Fatty Acid Synthase Inhibitors. Cell chemical biology. 26(9). 1322–1331.e4. 13 indexed citations

Hardwicke, Mary Ann, Alan R. Rendina, Shawn P. Williams, et al.. (2014). A human fatty acid synthase inhibitor binds β-ketoacyl reductase in the keto-substrate site. Nature Chemical Biology. 10(9). 774–779. 87 indexed citations

Isaacs, Richard C.A., Swati P. Mercer, Bruce D. Dorsey, et al.. (2010). P3 optimization of functional potency, in vivo efficacy and oral bioavailability in 3-aminopyrazinone thrombin inhibitors bearing non-charged groups at the P1 position. Bioorganic & Medicinal Chemistry Letters. 21(5). 1532–1535. 3 indexed citations

Isaacs, Richard C.A., Swati P. Mercer, Linda S. Payne, et al.. (2010). Design, synthesis and SAR of a series of 1,3,5-trisubstituted benzenes as thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 21(5). 1536–1540. 6 indexed citations

Hartman, Helen B., Stephen J. Gardell, Chris Petucci, et al.. (2009). Activation of farnesoid X receptor prevents atherosclerotic lesion formation in LDLR−/− and apoE−/− mice. Journal of Lipid Research. 50(6). 1090–1100. 122 indexed citations

Evans, Mark J., Paige E. Mahaney, Lisa Borges-Marcucci, et al.. (2009). A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. American Journal of Physiology-Gastrointestinal and Liver Physiology. 296(3). G543–G552. 79 indexed citations

Rossman, Eric I., Kun Liu, Robert E. Swillo, et al.. (2009). The Gap Junction Modifier, GAP-134 [(2S,4R)-1-(2-Aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic Acid], Improves Conduction and Reduces Atrial Fibrillation/Flutter in the Canine Sterile Pericarditis Model. Journal of Pharmacology and Experimental Therapeutics. 329(3). 1127–1133. 48 indexed citations

Isaacs, Richard C.A., Adel M. Naylor-Olsen, Daniel R. McMasters, et al.. (2008). Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 2: N-acetamidoimidazoles. Bioorganic & Medicinal Chemistry Letters. 18(6). 2062–2066. 9 indexed citations

10.

Gardell, Stephen J., Julie A. Krueger, Hassan Elokdah, et al.. (2007). Neutralization of Plasminogen Activator Inhibitor I (PAI-1) by the Synthetic Antagonist PAI-749 via a Dual Mechanism of Action. Molecular Pharmacology. 72(4). 897–906. 25 indexed citations

11.

Lyle, Terry A., Daniel R. McMasters, Philip E.J. Sanderson, et al.. (2006). Discovery of potent, selective 4-fluoroproline-based thrombin inhibitors with improved metabolic stability. Bioorganic & Medicinal Chemistry. 14(20). 6900–6916. 31 indexed citations

12.

Isaacs, Richard C.A., et al.. (2005). Structure-based design of novel groups for use in the P1 position of thrombin inhibitor scaffolds. Part 1: Weakly basic azoles. Bioorganic & Medicinal Chemistry Letters. 16(2). 338–342. 12 indexed citations

13.

Deng, James Z., Daniel R. McMasters, Peter Williams, et al.. (2005). Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization. Bioorganic & Medicinal Chemistry Letters. 15(20). 4411–4416. 35 indexed citations

14.

Stauffer, Kenneth J., Peter Williams, Terry A. Lyle, et al.. (2004). Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability. Bioorganic & Medicinal Chemistry Letters. 14(16). 4161–4164. 16 indexed citations

15.

Sanderson, Philip E.J., Matthew G. Stanton, Bruce D. Dorsey, et al.. (2003). Azaindoles: moderately basic P1 groups for enhancing the selectivity of thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(5). 795–798. 21 indexed citations

16.

Sanderson, Philip E.J., Adel M. Naylor-Olsen, Franklin C. Clayton, et al.. (2003). 3-Amino-4-sulfonylpyridinone acetamide and related pyridothiadiazine thrombin inhibitors. Bioorganic & Medicinal Chemistry Letters. 13(8). 1441–1444. 8 indexed citations

17.

Rittle, Kenneth E., James C. Barrow, Julie A. Krueger, et al.. (2003). Unexpected enhancement of thrombin inhibitor potency with o-aminoalkylbenzylamides in the P1 position. Bioorganic & Medicinal Chemistry Letters. 13(20). 3477–3482. 20 indexed citations

18.

Mao, Shi‐Shan, Craig T. Przysiecki, Julie A. Krueger, et al.. (1998). Selective Inhibition of Factor Xa in the Prothrombinase Complex by the Carboxyl-terminal Domain of Antistasin. Journal of Biological Chemistry. 273(46). 30086–30091. 7 indexed citations

19.

Feng, Dong-Mei, Stephen J. Gardell, Sidney D. Lewis, et al.. (1997). Discovery of a Novel, Selective, and Orally Bioavailable Class of Thrombin Inhibitors Incorporating Aminopyridyl Moieties at the P1 Position. Journal of Medicinal Chemistry. 40(23). 3726–3733. 53 indexed citations

20.

Friebe, S., et al.. (1995). HPLC on Calixarene Bonded Silica Gels. I. Characterization and Applications of the p-tert-Butyl-Calix[4]arene Bonded Material. Journal of Chromatographic Science. 33(6). 281–284. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact